ArticleCancer research2020
TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes.
Open access · greenAbstract readComment
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Origin recognition complex subunit 1 functions as an oncogenic driver and therapeutic target in cancer.Discover oncology · 2025Review
- Exploring PKMYT1 as a potential marker for colorectal cancer progression through bioinformatics analyses and experimental validation.Scientific reports · 2025Article
- KIF18B: an important role in signaling pathways and a potential resistant target in tumor development.Discover oncology · 2024Review
- miR-497 Target Gene Regulatory Network in Angiosarcoma.Molecular cancer research : MCR · 2024Article
- Role of non‑coding RNAs in UV‑induced radiation effects (Review).Experimental and therapeutic medicine · 2024Review
- Target gene regulatory network of miR-497 in angiosarcoma.bioRxiv : the preprint server for biology · 2023Article
- WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas.Cancers · 2023Article
- Molecular Alterations in Cutaneous Squamous Cell Carcinoma in Immunocompetent and Immunosuppressed Hosts-A Systematic Review.Cancers · 2023Review
- Screening and expression verification of key genes in cutaneous squamous cell carcinoma.Translational cancer research · 2022Article
- Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2022Review
- Lidocaine represses proliferation and cisplatin resistance in cutaneous squamous cell carcinomaBioengineered · 2022Article
- DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Investigating Cutaneous Squamous Cell CarcinomaFrontiers in medicine · 2022Review
- Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2021Review
- Review
- Loss of retinoic acid receptor-related receptor alpha (Rorα) promotes the progression of UV-induced cSCC.Cell death & disease · 2021Article
- TAp63-miRNA-AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma.Cancer research · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
13 authors at 5 institutions in 1 country.
Andrew John DavisDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Maksym TsinkevichDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6374-0650
Jason RodencalDepartment of Biology, Stanford University School of Medicine, Stanford, California.
Hussein A AbbasHematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xiao-Hua SuDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Young-Jin GiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bin FangDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Kimal RajapaksheDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Cristian CoarfaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-4183-4939
Preethi H GunaratneDepartment of Biology and Biochemistry, University of Houston, Houston, Texas.
John M KoomenDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-3818-1762
Kenneth Y TsaiDepartment of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Elsa R FloresDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Elsa.Flores@moffitt.org.ORCID 0000-0002-6173-2403
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USStanford University · USUniversity of Houston · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9MTranslational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Cheryl L. Walker · 2019 to 2026
$14.7MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MIdentification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinomaR35CA197452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FLORES, ELSA R · 2016 to 2022
$6.4MCenter for Clinical and Translational Sciences (CCTS)TL1TR000369 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$1.9MNCATS NIH HHS TL1 TR000369NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA125123NCI NIH HHS R35 CA197452NCI NIH HHS T32 CA009666NIEHS NIH HHS P30 ES030285
Abstract
TAp63 is a p53 family member and potent tumor and metastasis suppressor. Here, we show that
Indexed as
Carcinoma, Squamous CellMicroRNAsSkin NeoplasmsAnimalsAurora Kinase ACell ProliferationHumansKinesinsMembrane ProteinsMiceProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProteomicsUltraviolet RaysAURKA protein, humanAurora Kinase AKIF18B protein, humanKinesinsMembrane ProteinsMicroRNAsMIRN497 microRNA, humanPKMYT1 protein, humanProtein Serine-Threonine KinasesProtein-Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.